8D986787-7BD1-4F66-837E-88CD2A4CEA68
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 14.027595269382392
- age_years
- 36
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.706
- INTERFERON_GAMMA_RESPONSE+0.611
- E2F_TARGETS+0.572
- G2M_CHECKPOINT+0.533
- MYC_TARGETS_V1+0.532
- MYC_TARGETS_V2+0.463
- MTORC1_SIGNALING+0.455
- DNA_REPAIR+0.452
- NOTCH_SIGNALING+0.436
- IL6_JAK_STAT3_SIGNALING+0.433
Top 10 suppressed
- KRAS_SIGNALING_DN-0.391
- PANCREAS_BETA_CELLS-0.235
- SPERMATOGENESIS-0.224
- UV_RESPONSE_DN-0.189
- BILE_ACID_METABOLISM-0.130
- HEME_METABOLISM-0.073
- APICAL_SURFACE-0.062
- MYOGENESIS-0.045
- ESTROGEN_RESPONSE_EARLY-0.040
- XENOBIOTIC_METABOLISM+0.045
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 2B311620-94F3-4B53-B66A-81AC0A32453B | — | — | 0.959 |
| 2 | 81B10E10-884A-46EB-9F28-758D805FB9B1 | — | — | 0.956 |
| 3 | 795FBB8C-0E74-477F-AA27-1CE97A4E90B9 | — | — | 0.956 |
| 4 | A678E1E5-E02D-49A1-BB2B-C91A60E6382E | — | — | 0.953 |
| 5 | EB8F7B74-694A-4F9F-9C0B-F04006033CA4 | — | — | 0.953 |
| 6 | 30D8578D-0B48-4D03-9E39-6425494ECD5C | — | — | 0.951 |
| 7 | AF0A7BAA-D031-4C9F-91B7-7034F2C49D72 | — | — | 0.951 |
| 8 | 40CDF034-0EBC-42A1-BBD8-492C1494086E | — | — | 0.950 |
| 9 | SRR934949 | — | — | 0.949 |
| 10 | A9B59C46-7F32-4DD1-9649-B1788CA5E909 | — | — | 0.949 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 41 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.706 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.611 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.572 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.533 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.532 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.463 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.455 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.452 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.436 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.433 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.430 | Remibrutinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.426 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.423 | Idelalisib | — uncovered |
| APOPTOSIS | 0.373 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.365 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.365 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.354 | Inavolisib | — uncovered |
| COMPLEMENT | 0.326 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.325 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.311 | Idelalisib | — uncovered |